Czechia· CZ-0015003

IGAMAD

A anti-d (rh) immunoglobulin product containing human anti-d immunoglobulin, registered in Czechia by Instituto Grifols, S.A., Barcelona. The same ATC class is registered in 11 of our 19 countries.

ATC J06BB01

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedIGAMADATCJ06BB01REGISTER NO.CZ-0015003PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Anti-d (rh) immunoglobulin is registered in 11 of 19 countries.

Countries holding a registration under ATC J06BB01 (anti-d (rh) immunoglobulin), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 7 of them publish a price we can compare per daily dose

Anti-d (rh) immunoglobulin · ATC J06BB01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
HUMAN ANTI-D IMMUNOGLOBULIN
Manufacturer
Instituto Grifols, S.A., Barcelona
Country
Czechia (CZ)
ATC code
J06BB01
ATC class
Anti-D (rh) immunoglobulin
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0015003
    1X2ML
    CZK 1392.2

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Anti-d (rh) immunoglobulin in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All anti-d (rh) immunoglobulin products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Rhesonativ, Rhophylac
  • Belgium · Immunorho, Rhophylac
  • Bulgaria · Резонатив
  • Cyprus · Rhesonativ, Rhophylac
  • Germany · Rhesonativ, Rhophylac
  • Denmark · Rhesonativ, Rhophylac
  • Estonia · Rhesonativ
  • Spain · Igamad, Rhophylac
  • Finland · Rhophylac
  • France · Rhesonativ, Rhophylac
  • United Kingdom (Northern Ireland) · D-Gam, Rhophylac
  • Greece · Rhophylac
  • Hungary · Rhesonativ, Rhophylac
  • Ireland · Rhophylac
  • Iceland · Rhesonativ, Rhophylac
  • Italy · Igamad, Immunorho
  • Lithuania · Rhesonativ
  • Luxembourg · Rhesonativ, Rhophylac
  • Latvia · Rhesonativ
  • Malta · Rhesonativ, Rhophylac
  • Netherlands · Rhesonativ, Rhophylac
  • Norway · Rhesonativ, Rhophylac
  • Poland · Gamma Anty-D, Rhesonativ
  • Portugal · Rhesonativ, Rhophylac
  • Romania · Rhesonativ, Rhophylac
  • Sweden · Rhesonativ, Rhophylac
  • Slovenia · Rhesonativ, Rhophylac
  • Slovakia · Igamad, Rhesonativ

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b37ca6b2-b9f1-4c1e-935a-058038bcecfb
GET /v1/drugs/b37ca6b2-b9f1-4c1e-935a-058038bcecfb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL ISP",
  "source": "sukl",
  "strength": "1500IU",
  "pack_size": "1X2ML",
  "substance": "HUMAN ANTI-D IMMUNOGLOBULIN",
  "cz_kod_sukl": "0015003",
  "product_type": "KR/B",
  "substance_codes": "3530",
  "registration_state": "R",
  "registration_number": "59/596/07-C"
}

See everything about anti-d (rh) immunoglobulin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.